Another study suggested that a combination of the PI3K inhibitor LY294002 and conventional chemotherapy (paclitaxel) may provide an effective approach to inhibiting tumor growth and ascites production in ovarian cancer with acceptable side effects [438]. Here, PIK3CA is linked to ovarian cancer.